Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Teva Pharmaceutical Industries stock

TEVA.TA
IL0006290147
906517

Price

1,549.25
Today +/-
-59.42
Today %
-4.05 %

Teva Pharmaceutical Industries stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Teva Pharmaceutical Industries stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Teva Pharmaceutical Industries stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Teva Pharmaceutical Industries stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Teva Pharmaceutical Industries's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Teva Pharmaceutical Industries Stock Price History

DateTeva Pharmaceutical Industries Price
3/6/20251,549.25 undefined
3/5/20251,613.36 undefined
3/4/20251,559.28 undefined
3/3/20251,622.07 undefined
3/2/20251,637.60 undefined
2/27/20251,665.77 undefined
2/26/20251,699.79 undefined
2/25/20251,659.81 undefined
2/24/20251,653.89 undefined
2/23/20251,683.85 undefined
2/20/20251,741.32 undefined
2/19/20251,685.34 undefined
2/18/20251,694.17 undefined
2/17/20251,654.91 undefined
2/16/20251,646.76 undefined
2/13/20251,667.53 undefined
2/12/20251,641.29 undefined
2/11/20251,654.64 undefined
2/10/20251,674.20 undefined
2/9/20251,673.92 undefined
2/6/20251,744.70 undefined

Teva Pharmaceutical Industries Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Teva Pharmaceutical Industries, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Teva Pharmaceutical Industries from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Teva Pharmaceutical Industries’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Teva Pharmaceutical Industries. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Teva Pharmaceutical Industries’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Teva Pharmaceutical Industries’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Teva Pharmaceutical Industries’s growth potential.

Teva Pharmaceutical Industries Revenue, EBIT and net profit per share

DateTeva Pharmaceutical Industries RevenueTeva Pharmaceutical Industries EBITTeva Pharmaceutical Industries Net Income
2027e18.1 B undefined4.86 B undefined3.31 B undefined
2026e17.63 B undefined4.4 B undefined3.05 B undefined
2025e17.42 B undefined4.32 B undefined2.93 B undefined
202416.54 B undefined3.59 B undefined-1.64 B undefined
202315.85 B undefined3.54 B undefined-559 M undefined
202214.93 B undefined3.19 B undefined-2.45 B undefined
202115.88 B undefined3.42 B undefined417 M undefined
202016.66 B undefined3.17 B undefined-3.99 B undefined
201916.89 B undefined2.75 B undefined-999 M undefined
201818.85 B undefined3.16 B undefined-2.4 B undefined
201722.39 B undefined3.99 B undefined-16.53 B undefined
201621.9 B undefined4.56 B undefined68 M undefined
201519.65 B undefined4.74 B undefined1.57 B undefined
201420.27 B undefined4.47 B undefined3.06 B undefined
201320.31 B undefined3.93 B undefined1.27 B undefined
201220.32 B undefined3.55 B undefined1.96 B undefined
201118.31 B undefined4.01 B undefined2.76 B undefined
201016.12 B undefined4.28 B undefined3.33 B undefined
200913.9 B undefined3.04 B undefined2 B undefined
200811.09 B undefined1.27 B undefined635 M undefined
20079.41 B undefined2.4 B undefined1.95 B undefined
20068.41 B undefined897 M undefined546 M undefined
20055.25 B undefined1.31 B undefined1.07 B undefined

Teva Pharmaceutical Industries Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)NET INCOME (B)NET INCOME GROWTH (%)SHARES (B)DOCUMENTS
1983198419851986198719881989199019911992199319941995199619971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e
0.070.130.150.180.220.480.610.820.320.40.50.730.810.951.121.121.281.752.082.523.284.85.258.419.4111.0913.916.1218.3120.3220.3120.2719.6521.922.3918.8516.8916.6615.8814.9315.8516.5417.4217.6318.1
-81.9412.2121.7725.14112.9527.2534.43-60.6623.3626.7745.0211.4017.6317.09-0.0914.8736.5118.6921.2830.0546.499.4060.1511.8917.8325.3915.9913.5910.95-0.01-0.21-3.0611.452.20-15.77-10.43-1.35-4.69-6.006.174.405.311.182.69
4.1732.0631.9732.4033.9335.0135.7537.9936.4538.8942.6338.6036.6237.7439.0337.7240.1739.5440.7843.4746.3746.6647.2650.6551.8453.8453.0056.2351.9652.4352.7154.5457.7953.2047.4244.0044.6346.7649.5349.8450.3350.1247.5947.0445.81
00.040.050.060.080.170.220.310.120.150.210.280.30.360.440.420.520.690.851.11.522.242.484.264.885.977.379.079.5210.6510.7111.0611.3611.6510.628.37.547.797.867.447.988.29000
00.010.010.020.020.030.040.050.020.030.060.070.070.070.10.070.120.150.280.410.690.331.070.551.950.6423.332.761.961.273.061.570.07-16.53-2.4-1-3.990.42-2.45-0.56-1.642.933.053.31
-350.0044.4415.3840.0028.5733.3344.44-55.7739.1378.1319.302.944.2938.36-31.6871.0125.4287.8447.4868.54-51.95222.89-49.07257.51-67.47214.9666.55-17.17-28.85-35.35140.74-48.51-95.68-24,401.47-85.48-58.36299.40-110.45-686.57-77.15193.20-279.014.028.39
0.240.240.280.280.330.350.350.410.410.430.440.490.490.490.50.50.50.530.560.560.610.690.680.810.830.820.90.920.890.870.850.860.860.961.021.021.091.11.111.111.121.13000
---------------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Teva Pharmaceutical Industries Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Teva Pharmaceutical Industries is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (B)OTHER CURRENT LIAB. (B)CURRENT ASSETS (B)TANGIBLE ASSETS (B)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (B)GOODWILL (B)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (B)OTHER EQUITY (B)UNREAL. GAINS/LOSSES (M)EQUITY (B)LIABILITIES (B)PROVISIONS (B)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (B)LONG-TERM DEBT PORTION (B)SHORT-TERM REC. (B)LONG-T. LIAB. (B)DEFERRED TAXES (B)OTHER LIAB. (B)LONG-T. LIABILITIES (B)DEBT (B)TOTAL CAPITAL (B)
198319841985198619871988198919901991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                                                   
00.010.030.030.070.030.010.030.040.020.060.050.080.070.060.050.090.430.791.051.381.042.212.042.881.912.251.281.12.881.042.236.961.670.981.781.982.182.172.83.233.3
0.010.030.060.060.060.120.190.220.330.130.130.190.240.330.240.280.360.540.650.861.031.481.772.923.554.655.025.486.215.575.345.415.357.527.135.825.684.584.533.73.413.06
0000000000000068991041371672193003984110000000000000000000
0.020.030.040.050.070.10.140.160.240.110.150.160.230.330.30.350.350.50.570.781.011.291.111.882.443.43.333.875.015.55.054.373.974.954.924.734.424.43.823.834.023.01
000000000000000000000000.811.471.541.622.132.42.292.392.133.082.351.461.391.842.061.721.833.19
0.040.070.130.140.20.250.340.410.620.260.340.40.550.730.670.780.911.612.182.93.724.25.517.649.8611.4312.1412.2414.4516.3613.7214.418.417.2315.3813.7913.4613.0112.5712.0512.4912.55
0.020.040.050.050.070.150.190.20.280.120.140.190.380.410.420.460.480.530.550.680.831.281.362.192.523.73.774.365.956.326.646.546.548.077.676.876.956.866.486.166.154.95
3619199108893282748172133321001423144458634115446324255346320000008361000000
000000000000000000000000000000000000000000
000.020.020.020.070.080.080.110.050.060.060.070.090.080.170.290.610.590.180.280.720.651.991.924.584.055.7510.327.756.485.517.6821.4917.6414.0111.238.927.476.275.394.42
00000000000000000000.560.652.572.468.048.4112.312.6715.2318.2918.8618.9818.4119.0344.4128.4124.9224.8520.6220.0417.6317.1815.15
000000000000000000000000.070.080.480.640.841.131.341.71.572.591.861.421.040.981.231.111.92.282.26
0.030.040.090.090.10.240.280.290.40.180.230.280.490.520.520.660.81.251.281.732.25.434.8812.8313.5521.4821.6726.8135.6934.2533.7932.0235.8475.8355.2346.8944.0137.6435.0931.9630.9926.77
0.060.110.220.230.310.490.620.71.020.430.570.681.041.241.191.441.712.863.464.635.929.6310.3920.4723.4132.933.8139.0550.1450.6147.5146.4254.2393.0670.6260.6857.4750.6447.6744.0143.4839.33
                                                                                   
0.020.040.040.050.10.110.120.120.240.10.10.120.170.170.170.180.180.030.030.030.030.040.040.050.050.050.0521.950.050.050.050.053.343.673.690.060.060.060.060.060.060.06
000.010.010.010.010.020.020.030.010.010.010.010-0-0-0.020.480.480.481.163.043.397.888.2511.512.88013.3713.4713.6314.1217.7623.4123.4827.2127.3127.4427.5627.6927.8127.76
00.010.020.040.060.080.120.160.240.110.160.220.320.380.460.510.60.730.971.351.962.173.083.45.045.296.66011.2812.3512.5414.4414.8513.61-3.8-5.96-6.96-10.95-10.53-12.98-13.53-15.17
-0-0000000000000000-0.05-0.060.020.180.380.150.651.370.390.560-0.59-0.02-0.1-1.25-2.27-3.15-1.85-2.46-2.31-2.4-2.68-2.84-2.7-3.15
0000000000000000000000000000005-93312-7-41000000
0.020.050.080.10.170.20.260.30.50.220.270.350.490.550.630.680.771.181.421.883.345.636.6611.9714.7117.2220.1521.9524.1225.8526.1227.263437.5321.5118.8518.114.1514.4111.9311.639.5
0.020.030.050.050.060.110.130.120.180.070.10.10.180.180.10.120.110.440.530.791.051.641.890.611.382.242.682.533.573.383.323.171.922.162.071.851.721.761.691.892.62.2
000000000000000000000000.77000000002.394.263.562.742.682.582.882.813.483.5
000000000000000.090.090.150000001.942.153.333.625.946.367.046.847.367.118.798.647.526.935.645.044.664.495.31
0000000000000000000000000000000.9900.62.470.770.520.510.510.020.020.020.02
0.010.010.020.020.030.070.050.110.160.090.110.140.260.340.240.330.280.340.210.740.640.560.380.741.842.911.31.433.752.480.821.760.990.812.881.71.832.671.42.091.651.76
0.030.050.070.070.090.180.180.240.330.170.210.240.440.520.430.540.540.780.741.531.72.22.264.075.378.487.69.8913.6812.8911.9712.2913.0118.4917.9214.3213.6713.1611.0311.4712.2512.8
000.040.030.030.080.140.140.150.040.070.080.090.160.130.20.390.550.910.810.451.511.314.593.355.544.314.1110.2411.719.958.528.3532.5228.8326.6924.5622.7321.6219.118.1616
000000000000000.010.030.030.070.040.040.040.210.220.490.461.721.742.052.611.851.251.11.755.413.282.141.10.960.780.550.610.48
0.010.010.0100.030.040.040.050.040.020.020.010.020.02000.010.30.390.420.440.30.540.150.480.80.911.281.291.711.151.211.641.851.743.082.722.994.294.344.33
0.010.010.050.040.050.110.190.190.190.050.080.090.110.180.150.240.430.921.341.270.932.032.085.224.288.066.957.1614.1214.8512.9110.7811.339.5833.9530.5728.7326.4225.423.9423.1120.81
0.040.050.120.110.140.290.370.420.520.220.290.330.550.710.580.780.971.72.082.792.624.234.349.299.6516.5414.5517.0527.827.7424.8723.0724.3158.0651.8744.8942.4139.5836.4235.4135.3533.61
0.060.110.190.210.310.490.630.721.030.440.570.681.051.251.21.451.742.893.54.675.969.861121.2724.3633.7734.73951.9253.650.9950.3358.395.673.3863.7460.5153.7350.8347.3546.9943.11
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Teva Pharmaceutical Industries provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Teva Pharmaceutical Industries's financial health and stability.

Assets

Teva Pharmaceutical Industries's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Teva Pharmaceutical Industries must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Teva Pharmaceutical Industries after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Teva Pharmaceutical Industries's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (B)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (B)NON-CASH ITEM (B)PAID INTEREST (B)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (B)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
0.020.030.040.050.020.030.060.070.070.070.10.070.120.150.280.410.690.331.070.551.950.6423.342.771.911.253.041.60.31-16.45-2.47-1-4.10.46-2.41-0.62
0.010.020.020.030.010.020.020.030.030.040.050.060.070.10.110.10.130.220.240.430.520.970.910.981.071.7101.511.311.522.111.841.721.561.331.311.15
03-2-124-2-2-4-82033-30-31-2827-7-8911127-140-199-500-6900-22623715-2,331-837-985-696-120-1,059-317
0-0.07-0.05-0.04-0.03-0.02-0.04-0.060-0.130.02-0.07-0.06-0.11-0.14-0.15-0.090.030.09-0.22-0.850.080.45-0.210.590.410.970.290.97-0.12-1.65-1.82-0.9-2.19-1.71.26-0.07
0-000.010-0-0000.01-00.010.020.040.030.03-0.070.64-0.031.390.081.520.160.220.21.231.020.511.432.1620.545.741.916.640.832.491.22
0.010.020.020.030.010.010.010.020.020.030.030.030.040.050.040.030.030.030.030.120.180.150.190.190.230.300.290.240.290.80.820.840.850.910.951.08
981116131518232925212422257554134249180284197160193542766140675802341106420552709495543298
0.03-0.020.010.060.010.030.040.050.11-0.010.190.070.150.170.270.350.631.251.372.061.813.233.374.144.134.573.245.135.543.892.232.450.751.220.81.591.37
-21-51-33-44-21-28-38-81-86-85-68-59-75-111-134-185-226-338-333-390-542-681-719-710-1,053-1,1040-929-772-901-874-651-525-578-562-548-526
-0.05-0.08-0.03-0.05-0.05-0.04-0.05-0.09-0.13-0.13-0.07-0.13-0.27-0.08-0.19-0.66-0.44-2.4-0.54-4.06-1.35-4.14-0.92-5.46-7.6-1.13-1.15-1.45-5.57-34.413.451.871.360.861.520.660.97
-0.02-0.030.01-0.01-0.03-0.02-0.02-0-0.04-0.040-0.07-0.190.03-0.06-0.48-0.21-2.06-0.2-3.67-0.81-3.46-0.2-4.75-6.55-0.03-1.15-0.52-4.79-33.54.322.521.881.442.091.21.49
0000000000000000000000000000000000000
-0.010.03-0.020.050.010.030.050.060.060.15-0.120.080.170.290.310.380.071.080.12.26-0.16-0.23-1.881.155.030.320-1.22-0.3926.25-4.48-3.27-1.86-1.88-2.17-1.37-1.7
0.050.040.050000000000.010.010.010.010.040.080.130.180.210.190.170.08-0.83-1.1500.016.530.690000000
0.040.0600.020.030.020.040.040.040.13-0.130.060.150.270.270.340.030.85-0.312.02-0.361.36-2.270.573.34-1.68-3.88-2.384.8125.22-5.75-3.35-1.93-1.89-2.17-1.49-1.91
0.010-0.02-0.020.030-00-0-00-0-0.01-0-0.01-0.010-0.19-0.38-0.19-0.121.78-0.020.01-0.070.01-3.88-0.01-0.18-0.17-0.11-0.06-0.01-0.01-0.01-0.12-0.21
-3-8-7-10-4-5-7-17-14-14-21-20-17-27-32-46-76-120-162-229-299-388-528-668-800-8550-1,156-1,155-1,558-1,161-22-520000
0.02-0.04-0.010.03-00.010.0300.02-0-0.01-00.030.340.350.040.25-0.270.490.060.160.370.14-0.75-0.151.78-1.841.194.72-5.96-0.030.820.190.20.020.640.39
4.7-76-2715-13-2.3-1.8-35.920.2-91.9125.410.57853.7139168.1400.5910.31,036.41,6681,2712,5502,6543,4263,0813,4683,2374,1984,7702,9891,3511,7952236382361,042842
0000000000000000000000000000000000000

Teva Pharmaceutical Industries stock margins

The Teva Pharmaceutical Industries margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Teva Pharmaceutical Industries. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Teva Pharmaceutical Industries.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Teva Pharmaceutical Industries's sales revenue. A higher gross margin percentage indicates that the Teva Pharmaceutical Industries retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Teva Pharmaceutical Industries's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Teva Pharmaceutical Industries's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Teva Pharmaceutical Industries's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Teva Pharmaceutical Industries. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Teva Pharmaceutical Industries's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Teva Pharmaceutical Industries Margin History

Teva Pharmaceutical Industries Gross marginTeva Pharmaceutical Industries Profit marginTeva Pharmaceutical Industries EBIT marginTeva Pharmaceutical Industries Profit margin
2027e50.12 %26.83 %18.28 %
2026e50.12 %24.98 %17.31 %
2025e50.12 %24.81 %16.85 %
202450.12 %21.69 %-9.91 %
202350.33 %22.34 %-3.53 %
202249.84 %21.34 %-16.39 %
202149.53 %21.53 %2.63 %
202046.76 %19.01 %-23.95 %
201944.63 %16.27 %-5.92 %
201844 %16.73 %-12.72 %
201747.42 %17.84 %-73.82 %
201653.2 %20.81 %0.31 %
201557.79 %24.11 %8 %
201454.54 %22.06 %15.07 %
201352.71 %19.32 %6.25 %
201252.43 %17.47 %9.66 %
201151.96 %21.9 %15.07 %
201056.23 %26.56 %20.66 %
200953 %21.89 %14.39 %
200853.84 %11.45 %5.73 %
200751.84 %25.46 %20.75 %
200650.65 %10.67 %6.49 %
200547.26 %25.01 %20.42 %

Teva Pharmaceutical Industries Stock Sales Revenue, EBIT, Earnings per Share

The Teva Pharmaceutical Industries earnings per share therefore indicates how much revenue Teva Pharmaceutical Industries has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Teva Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Teva Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Teva Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Teva Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Teva Pharmaceutical Industries Revenue, EBIT and net profit per share

DateTeva Pharmaceutical Industries Sales per ShareTeva Pharmaceutical Industries EBIT per shareTeva Pharmaceutical Industries Earnings per Share
2027e15.97 undefined0 undefined2.92 undefined
2026e15.55 undefined0 undefined2.69 undefined
2025e15.37 undefined0 undefined2.59 undefined
202414.63 undefined3.17 undefined-1.45 undefined
202314.16 undefined3.16 undefined-0.5 undefined
202213.45 undefined2.87 undefined-2.2 undefined
202114.34 undefined3.09 undefined0.38 undefined
202015.21 undefined2.89 undefined-3.64 undefined
201915.48 undefined2.52 undefined-0.92 undefined
201818.47 undefined3.09 undefined-2.35 undefined
201722.03 undefined3.93 undefined-16.26 undefined
201622.79 undefined4.74 undefined0.07 undefined
201522.75 undefined5.48 undefined1.82 undefined
201423.63 undefined5.21 undefined3.56 undefined
201323.9 undefined4.62 undefined1.49 undefined
201223.27 undefined4.07 undefined2.25 undefined
201120.51 undefined4.49 undefined3.09 undefined
201017.5 undefined4.65 undefined3.62 undefined
200915.51 undefined3.4 undefined2.23 undefined
200813.52 undefined1.55 undefined0.77 undefined
200711.33 undefined2.89 undefined2.35 undefined
200610.44 undefined1.11 undefined0.68 undefined
20057.71 undefined1.93 undefined1.57 undefined

Teva Pharmaceutical Industries business model

Teva Pharmaceutical Industries Ltd is a leading global company in the pharmaceutical industry. The company was founded in 1901 in Jerusalem, Israel, as Salomon, Levin and Company. The name Teva was adopted later in 1976. Teva's business model focuses on manufacturing and distributing high-quality and affordable pharmaceuticals worldwide. The company specializes in generics, as well as specialty pharmaceuticals. Teva has made a name for itself through its strong brand presence, focus on developing affordable medications, and production of biosimilars. Teva is divided into various divisions that focus on the manufacturing and distribution of pharmaceuticals. One of these divisions is the generics division, in which the company targets both the domestic and international markets. Teva's research and development division is known for developing biotechnology-based medications. The specialty pharmaceuticals division focuses on rare and difficult-to-treat diseases, such as multiple sclerosis and Parkinson's disease, and develops new treatment options. Teva is also commercially active in the field of biosimilars, which offer medications based on biological sources. These medications offer higher efficacy and fewer side effects than conventional medications. Teva has taken a leading role in this division by offering medications with high standards, serving a significant growth market. The company offers a variety of products, including prescription medications, over-the-counter products, and veterinary medicine. Some of Teva's popular products include Azilect (a medication for Parkinson's treatment), Copaxone (a medication for multiple sclerosis treatment), QVAR (a medication for asthma treatment), Azor (a medication for hypertension treatment), and ProAir (a medication for asthma treatment). Teva has a long-standing history in the pharmaceutical industry and has established an impressive global presence. The company has strong structures not only in Israel but also in other countries such as the United States, Europe, and Asia. It has maintained an impressive growth strategy and has become a major player in global healthcare. Overall, Teva has established itself as a key company in the pharmaceutical industry. It has a strong focus on affordability and quality of medications, with particular emphasis on the development of biosimilars and biotechnology. The company has a wide range of products and divisions that cater to the needs of customers worldwide. Teva Pharmaceutical Industries is one of the most popular companies on Eulerpool.com.

Teva Pharmaceutical Industries SWOT Analysis

Strengths

Teva Pharmaceutical Industries is a leading multinational pharmaceutical company with a strong global presence. It operates in over 60 countries and has a wide distribution network, allowing it to reach a large customer base worldwide.

Teva offers a diverse range of pharmaceutical products, including both generic and branded drugs. This diversity helps in mitigating risks associated with any potential decline in specific product lines and provides a balanced revenue stream.

Teva has a strong focus on research and development (R&D), investing significantly in the development of innovative drugs and technologies. This enables the company to introduce new and improved products, stay competitive in the market, and drive future growth.

Weaknesses

Despite having a diversified product portfolio, Teva's revenue heavily relies on a few key products. Any decline in the sales of these products due to patent expirations or generic competition can significantly impact the company's financial performance.

The pharmaceutical industry is subject to strict regulations and legal challenges. Teva faces the risk of lawsuits, such as patent disputes or allegations of improper marketing practices, which can lead to financial penalties and reputational damage.

Opportunities

The increasing cost of healthcare and expiring patents of branded drugs present an opportunity for Teva to capitalize on the growing demand for generic drugs. By leveraging its expertise in generic pharmaceuticals, the company can expand its market share and profitability.

Emerging markets, such as Asia and Latin America, offer significant growth potential for pharmaceutical companies. Teva can explore expansion opportunities in these markets by forming strategic partnerships, acquiring local companies, or establishing manufacturing facilities.

Threats

The generic pharmaceutical industry is highly competitive, with numerous players vying for market share. Teva faces the risk of price erosion and margin pressure due to intense competition, potentially impacting its profitability.

The expiration of patents on key drugs can lead to increased competition from generic manufacturers. Teva's revenue may decline if it fails to effectively replace the lost revenue with new products or face significant generic competition for its existing products.

Teva Pharmaceutical Industries Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
Product12.98 B USD12.77 B USD13.83 B USD14.35 B USD14.51 B USD2.15 B USD-
Distribution Service1.62 B USD1.52 B USD1.39 B USD1.5 B USD1.51 B USD602 M USD-
Product and Service, Other570 M USD428 M USD500 M USD680 M USD716 M USD230 M USD-
License681 M USD212 M USD160 M USD129 M USD147 M USD22 M USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
Generics Medicians1.59 B USD1.59 B USD1.65 B USD1.79 B USD1.89 B USD3.59 B USD-
Anda1.58 B USD1.47 B USD1.32 B USD1.46 B USD1.49 B USD1.35 B USD-
Austedo1.23 B USD963 M USD802 M USD637 M USD412 M USD204 M USD-
BENDEKA and TREANDA241 M USD316 M USD385 M USD415 M USD496 M USD642 M USD-
Other Products281 M USD246 M USD295 M USD309 M USD271 M USD656 M USD-
Respiratory Product265 M USD273 M USD356 M USD353 M USD354 M USD--
COPAXONE39 M USD36 M USD37 M USD53 M USD63 M USD535 M USD-
Pro Air--180 M USD241 M USD274 M USD--
Distribution----20 M USD602 M USD-
QVAR---179 M USD250 M USD182 M USD-
Respiratory product-----402 M USD-
Pro air-----397 M USD-
AJOVY44 M USD35 M USD50 M USD31 M USD93 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
Branded------5.69 B USD
Generics------5.04 B USD
Other Products------1.25 B USD

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
International Markets1.96 B USD1.9 B USD2.03 B USD2.15 B USD2.25 B USD--
Other Activities926 M USD1.05 B USD1.15 B USD1.3 B USD1.3 B USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
North America Segment8.12 B USD7.45 B USD7.81 B USD8.45 B USD---
Europe Segment4.84 B USD4.53 B USD4.89 B USD4.76 B USD---
Generics------12.26 B USD
Specialty------7.91 B USD
International markets-----3.01 B USD-
Other Activities-----1.37 B USD-

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Teva Pharmaceutical Industries Revenue by Segment

Segmente2023202220212020201920182017
North America segment-----9.3 B USD-
North America Segment----8.54 B USD--
Europe segment-----5.19 B USD-
Europe Segment----4.8 B USD--

Teva Pharmaceutical Industries Revenue by Region

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Teva Pharmaceutical Industries Revenue by Segment

DateEuropeEurope Group TwoNorth AmericaRest Of The WorldUs Group One
20234.84 B USD-8.12 B USD--
20224.53 B USD-7.45 B USD--
20214.89 B USD-7.81 B USD--
20204.76 B USD-8.45 B USD--
20194.8 B USD-8.54 B USD--
20185.19 B USD-9.3 B USD--
2017-3.99 B USD-3.23 B USD5.04 B USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Teva Pharmaceutical Industries Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Teva Pharmaceutical Industries historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Teva Pharmaceutical Industries shares outstanding

The number of shares was Teva Pharmaceutical Industries in 2024 — This indicates how many shares 1.131 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Teva Pharmaceutical Industries earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Teva Pharmaceutical Industries's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Teva Pharmaceutical Industries’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Teva Pharmaceutical Industries's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Teva Pharmaceutical Industries dividend history and estimates

In 2024, Teva Pharmaceutical Industries paid a dividend amounting to 0 USD. Dividend means that Teva Pharmaceutical Industries distributes a portion of its profits to its owners.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Dividend
Dividend (Estimate)
Details

Dividend

ⓘ

Dividend Overview

The dividend per year chart for Teva Pharmaceutical Industries provides a comprehensive view of the annual dividends distributed to shareholders. Analyze the trend to understand the consistency and growth in dividend payouts over the years.

Interpretation and Use

A consistent or increasing trend in dividends can indicate the company's profitability and financial health. Investors can use this data to identify Teva Pharmaceutical Industries’s potential for long-term investment and income generation through dividends.

Investment Strategy

Incorporate the dividend data in evaluating Teva Pharmaceutical Industries's overall performance. A thorough analysis, considering other financial aspects, will help in making informed investment decisions for optimal capital growth and income generation.

Teva Pharmaceutical Industries Dividend History

DateTeva Pharmaceutical Industries Dividend
2027e113.7 undefined
2026e105.75 undefined
2025e101.5 undefined
20173.1 undefined
20165.37 undefined
20155.25 undefined
20144.84 undefined
20134.6 undefined
20124 undefined
20113.2 undefined
20102.8 undefined
20092.4 undefined
20081.8 undefined
20071.6 undefined
20061.36 undefined
20050.3 undefined

Teva Pharmaceutical Industries dividend payout ratio

In 2024, Teva Pharmaceutical Industries had a payout ratio of 3,838.66%. The payout ratio indicates the percentage of the company's profits that Teva Pharmaceutical Industries distributes as dividends.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Payout ratio
Details

Payout ratio

ⓘ

What is Yearly Payout Ratio?

The yearly payout ratio for Teva Pharmaceutical Industries represents the proportion of earnings paid out as dividends to shareholders. It is an indicator of the company's financial health and stability, illustrating how much profit is being returned to investors versus being reinvested back into the company.

How to Interpret the Data

A lower payout ratio for Teva Pharmaceutical Industries could mean that the company is reinvesting more into its growth, whereas a higher ratio indicates more earnings are being distributed as dividends. Investors seeking regular income might prefer companies with a higher payout ratio, while those looking for growth may opt for companies with a lower ratio.

Using the Data for Investments

Evaluate Teva Pharmaceutical Industries's payout ratio in conjunction with other financial metrics and performance indicators. A sustainable payout ratio, coupled with strong financial health, can indicate a reliable dividend payout. However, a very high ratio might suggest the company is not sufficiently reinvesting in its future growth.

Teva Pharmaceutical Industries Payout Ratio History

DateTeva Pharmaceutical Industries Payout ratio
2027e3,896.18 %
2026e3,928.73 %
2025e3,921.14 %
20243,838.66 %
20234,026.4 %
20223,898.37 %
20213,591.2 %
20204,589.62 %
20193,514.29 %
20182,669.7 %
2017-19.09 %
20167,584.89 %
2015288.27 %
2014135.93 %
2013308.72 %
2012177.78 %
2011103.56 %
201077.35 %
2009107.62 %
2008230.77 %
200768.09 %
2006197.1 %
200518.87 %
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Teva Pharmaceutical Industries.

Teva Pharmaceutical Industries latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
12/31/20240.7 0.71  (2.01 %)2024 Q4
9/30/20240.67 0.69  (3.02 %)2024 Q3
6/30/20240.58 0.61  (4.92 %)2024 Q2
3/31/20240.53 0.48  (-8.97 %)2024 Q1
12/31/20230.78 1  (28.49 %)2023 Q4
9/30/20230.61 0.6  (-1.59 %)2023 Q3
6/30/20230.54 0.56  (3.65 %)2023 Q2
3/31/20230.58 0.4  (-30.51 %)2023 Q1
12/31/20220.78 0.71  (-8.41 %)2022 Q4
9/30/20220.64 0.59  (-7.45 %)2022 Q3
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Teva Pharmaceutical Industries stock

Eulerpool World ESG Rating (EESG©)

80/ 100

🌱 Environment

63

👫 Social

89

🏛️ Governance

88

Environment

Scope 1 - Direct Emissions
253,306
Scope 2 - Indirect emissions from purchased energy
237,815
Scope 3 - Indirect emissions within the value chain
6,112,490
Total CO₂ emissions
491,121
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees46
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Teva Pharmaceutical Industries shareholders

%
Name
Stocks
Change
Date
3.25586 % Norges Bank Investment Management (NBIM)36,916,2961,513,93612/31/2024
2.61990 % The Vanguard Group, Inc.29,705,44861,7811/31/2025
0.21846 % CPP Investment Board2,477,000222,0003/31/2024
0.21512 % Charles Schwab Investment Management, Inc.2,439,13612,2501/31/2025
0.18285 % Elstein (Amir)2,073,22304/1/2024
0.13887 % Mignone (Roberto A.)1,574,57504/1/2024
0.10105 % APG Asset Management N.V.1,145,791-112,53512/31/2023
0.07897 % Dimensional Fund Advisors, L.P.895,3814,1931/31/2025
0.06044 % UBS Asset Management (UK) Ltd.685,346-1,1851/31/2025
0.04819 % Sabag (Mark)546,373-177,6262/12/2025
1
2
3
4
5
...
10

Teva Pharmaceutical Industries Executives and Management Board

Mr. Sven Dethlefs

(54)
Teva Pharmaceutical Industries Executive Vice President - North America Commercial
Compensation 4.06 M

Mr. Eliyahu Kalif

(50)
Teva Pharmaceutical Industries Chief Financial Officer, Executive Vice President
Compensation 4.01 M

Mr. Mark Sabag

(52)
Teva Pharmaceutical Industries Executive Vice President - International Markets Commercial
Compensation 3.92 M

Mr. Eric Drape

(61)
Teva Pharmaceutical Industries Executive Vice President - Global Operations
Compensation 3.91 M

Dr. Sol Barer

(75)
Teva Pharmaceutical Industries Independent Chairman of the Board
Compensation 539,999
1
2
3
4
...
5

Most common questions regarding Teva Pharmaceutical Industries

What values and corporate philosophy does Teva Pharmaceutical Industries represent?

Teva Pharmaceutical Industries Ltd represents values of integrity, quality, and accessibility in the pharmaceutical industry. With a strong corporate philosophy focused on making a positive impact on global health, Teva strives to provide affordable and innovative healthcare solutions to people around the world. By prioritizing patient needs, Teva emphasizes ethical business practices and promotes sustainable growth. As a leading global pharmaceutical company, Teva's commitment to improving and saving lives is evident in its extensive product portfolio, research initiatives, and dedication to making healthcare accessible to all.

In which countries and regions is Teva Pharmaceutical Industries primarily present?

Teva Pharmaceutical Industries Ltd is primarily present in various countries and regions globally. Some key regions include North America, Europe, Asia Pacific, Latin America, and the Middle East. In North America, Teva has a significant presence in the United States and Canada. In Europe, the company operates in countries such as Germany, France, Spain, Italy, and the United Kingdom. Teva also has a strong presence in countries like China, Japan, India, Australia, and South Korea, among others, in the Asia Pacific region. Moreover, Teva Pharmaceutical Industries Ltd has expanded its reach to Latin American countries like Brazil and Mexico, as well as the Middle East region.

What significant milestones has the company Teva Pharmaceutical Industries achieved?

Teva Pharmaceutical Industries Ltd has achieved significant milestones throughout its history. The company became the largest generic drug manufacturer in the world, offering affordable healthcare solutions to millions of patients worldwide. Teva's acquisition of Actavis Generics further enhanced its global market presence. It pioneered the development of cutting-edge medications and continues to drive innovation in the pharmaceutical industry. Teva's commitment to quality and patient-centric approach have earned it numerous recognitions and awards, solidifying its position as a leader in the market. With a dedicated focus on improving people's lives through accessible medicines, Teva Pharmaceutical Industries Ltd stands as a prominent player in the healthcare sector.

What is the history and background of the company Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries Ltd. is a leading global pharmaceutical company. Founded in 1901, Teva has a rich history and impressive background. Originally established in Jerusalem, Israel, Teva has grown to become the world's largest manufacturer of generic drugs. With a global network of research and development centers, manufacturing sites, and commercial operations in over 60 countries, Teva is committed to improving health and increasing access to high-quality healthcare solutions worldwide. The company has a diverse portfolio of products, spanning multiple therapeutic areas, including specialty medicines, generic drugs, and over-the-counter products. Teva's dedication to innovation, quality, and affordability has made it a trusted name in the pharmaceutical industry.

Who are the main competitors of Teva Pharmaceutical Industries in the market?

The main competitors of Teva Pharmaceutical Industries Ltd in the market include companies such as Pfizer, Novartis, Mylan, Johnson & Johnson, and GlaxoSmithKline. These companies also operate in the pharmaceutical industry and compete with Teva in areas such as generic drugs, specialty pharmaceuticals, and innovative health solutions.

In which industries is Teva Pharmaceutical Industries primarily active?

Teva Pharmaceutical Industries Ltd is primarily active in the pharmaceutical industry.

What is the business model of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries Ltd is a globally renowned pharmaceutical company. The company's business model centers around developing, manufacturing, and distributing generic and specialty medicines. With a focus on improving access to affordable healthcare, Teva offers a wide range of high-quality pharmaceutical products for various therapeutic areas. By combining its innovative research and development capabilities with extensive global reach, Teva aims to provide cost-effective solutions to patients worldwide. As a leading generics manufacturer, Teva leverages its expertise to deliver safe and effective medications, contributing to better healthcare outcomes globally.

What is the P/E ratio of Teva Pharmaceutical Industries 2025?

The Teva Pharmaceutical Industries P/E ratio is 597.01.

What is the P/S ratio of Teva Pharmaceutical Industries 2025?

The Teva Pharmaceutical Industries P/S ratio is 100.57.

What is the Quality Investing of Teva Pharmaceutical Industries?

The Quality Investing for Teva Pharmaceutical Industries is 1/10.

What is the revenue of Teva Pharmaceutical Industries 2025?

The expected Teva Pharmaceutical Industries revenue is 17.42 B USD.

How high is the profit of Teva Pharmaceutical Industries 2025?

The expected Teva Pharmaceutical Industries profit is 2.93 B USD.

What is the business model of Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd is one of the largest and most well-known pharmaceutical companies worldwide. The company is based in Israel and employs over 45,000 people around the world. It operates in various divisions and offers a wide range of products. The company's divisions include generics, specialty pharmaceuticals, and biopharmaceuticals. In the generics division, Teva offers a variety of generic medications that are available at an affordable price. These medications are essentially copies of brand-name drugs that are already on the market. Teva also operates in the specialty pharmaceuticals division. Here, the company focuses on the development and marketing of medications for rare diseases. These medications treat diseases where there are either no treatment options or where existing treatments are ineffective. The company is also active in the biopharmaceuticals division, where it focuses on the development and marketing of biologics. Biologics are medications made from living organisms. They are used to treat diseases such as cancer, arthritis, and multiple sclerosis. Some of Teva's products include Copaxone, Azilect, Qvar, ProAir, and NuvaRing. Copaxone is a medication for the treatment of multiple sclerosis and is Teva's top-selling drug. Azilect is used to treat Parkinson's disease. Qvar and ProAir are asthma medications, and NuvaRing is a hormonal contraceptive. Teva's business model is based on the development and marketing of pharmaceutical products to improve people's health. The company generates revenue through the sale of its products. Teva is a major player in the generic market and has a significant market share in this division. The company also has a strong presence in the specialty pharmaceuticals market. Teva also utilizes partnerships and acquisitions to expand its business and enter new markets. An important acquisition for Teva was the acquisition of Actavis Generics, which made Teva one of the largest generic pharmaceutical companies in the world. Overall, Teva Pharmaceutical Industries Ltd is a leading pharmaceutical company that offers a wide range of products and operates in various divisions. The company has a strong presence in the generic market and also focuses on the development of medications for rare diseases and biopharmaceuticals. Teva is expected to continue to grow and enter new markets through partnerships and acquisitions.

What is the Teva Pharmaceutical Industries dividend?

Teva Pharmaceutical Industries pays a dividend of 0 USD distributed over payouts per year.

How often does Teva Pharmaceutical Industries pay dividends?

The dividend cannot currently be calculated for Teva Pharmaceutical Industries or the company does not pay out a dividend.

What is the Teva Pharmaceutical Industries ISIN?

The ISIN of Teva Pharmaceutical Industries is IL0006290147.

What is the Teva Pharmaceutical Industries WKN?

The WKN of Teva Pharmaceutical Industries is 906517.

What is the Teva Pharmaceutical Industries ticker?

The ticker of Teva Pharmaceutical Industries is TEVA.TA.

How much dividend does Teva Pharmaceutical Industries pay?

Over the past 12 months, Teva Pharmaceutical Industries paid a dividend of 3.1 USD . This corresponds to a dividend yield of about 0.2 %. For the coming 12 months, Teva Pharmaceutical Industries is expected to pay a dividend of 105.75 USD.

What is the dividend yield of Teva Pharmaceutical Industries?

The current dividend yield of Teva Pharmaceutical Industries is 0.2 %.

When does Teva Pharmaceutical Industries pay dividends?

Teva Pharmaceutical Industries pays a quarterly dividend. This is distributed in the months of April, July, September, December.

How secure is the dividend of Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries paid dividends every year for the past 3 years.

What is the dividend of Teva Pharmaceutical Industries?

For the upcoming 12 months, dividends amounting to 105.75 USD are expected. This corresponds to a dividend yield of 6.83 %.

In which sector is Teva Pharmaceutical Industries located?

Teva Pharmaceutical Industries is assigned to the 'Health' sector.

Wann musste ich die Aktien von Teva Pharmaceutical Industries kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Teva Pharmaceutical Industries from 12/12/2017 amounting to 0.298 USD, you needed to have the stock in your portfolio before the ex-date on 11/28/2017.

When did Teva Pharmaceutical Industries pay the last dividend?

The last dividend was paid out on 12/12/2017.

What was the dividend of Teva Pharmaceutical Industries in the year 2024?

In the year 2024, Teva Pharmaceutical Industries distributed 0 USD as dividends.

In which currency does Teva Pharmaceutical Industries pay out the dividend?

The dividends of Teva Pharmaceutical Industries are distributed in USD.

All fundamentals about Teva Pharmaceutical Industries

Our stock analysis for Teva Pharmaceutical Industries Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Teva Pharmaceutical Industries Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.